Pharmaceutical Folding Carton Procurement: Why SBB C1S Ivory Board Requires USP Compliance for Blister Pack Backing

Why the Standards Stack on a Pharmaceutical Folding Carton Is Layered

A pharmaceutical folding carton is a packaging system, not a single material. The outer paperboard (typically SBB C1S ivory board) carries the print artwork and patient information. Inside, a blister pack holds the dosage form — the blister itself is usually PVC, PVDC, or cold-form aluminum, sealed against an aluminum lidding foil. The whole assembly has to protect the drug product for the full shelf life, typically 24–36 months, and it has to do that under different national pharmacopeias in every market it ships to.

The standards stack is layered because the components are layered. The paperboard is regulated by paper-and-paperboard rules; the plastic blister is regulated by plastic rules; the aluminum lidding is regulated by aluminum rules; the inks and adhesives that bind the system together are regulated by their own migration and elemental impurity rules. USP <661> sits at the top of the stack as the framework that ties the materials-of-construction expectations together for the drug product manufacturer.

What SBB C1S Ivory Board Actually Is

SBB C1S ivory board is Solid Bleached Board, Coated One Side. The fiber is bleached chemical pulp from sustainably managed plantations (typically eucalyptus, acacia, or a blend), giving the board its characteristic high brightness and clean surface. C1S means the top side is coated for high print quality; the back is uncoated for adhesive bonding during carton conversion.

For a pharmaceutical blister pack backing card the relevant properties are:

• Stiffness to keep the blister flat during filling, transport, and shelf life. SBB delivers the highest stiffness-per-caliper of any folding paperboard grade.
• Print surface for branded artwork, batch coding, regulatory text, and patient information leaflets glued to the back.
• Low fiber-shed for clean-room filling — loose fibers from a low-quality paperboard contaminate the blister sealing surface and cause lamination rejects on the production line.
• Surface energy and absorbency for ink adhesion and adhesive bonding.
• Purity profile from the bleached chemical pulp — lower in heavy metals and extractives than mechanical-pulp-containing FBB grades.

For pharmaceutical folding cartons, the practical choice between Folding Box Board (FBB, multi-ply with mechanical pulp middle layers) and Solid Bleached Board (SBB, single-ply bleached) is usually decided by the converter’s converting spec and the drug product manufacturer’s compliance review. SBB C1S is often the preferred grade for higher-value or longer-shelf-life drug products because the purity profile simplifies the compliance documentation.

What USP <661> Actually Covers

USP General Chapter <661> is the US Pharmacopeia chapter titled Plastic Packaging Systems and Their Materials of Construction. Its scope covers the materials that come into contact with a drug product during packaging, storage, and administration, and the biocompatibility expectations those materials have to meet.

A literal reading of the chapter title says “plastic” and the paperboard in a folding carton is not a plastic. But the chapter applies to the packaging system as a whole, and a pharmaceutical procurement team that wants the whole system to clear USP <661> is right to expect the paperboard supplier to anchor the documentation. A Ningbo ivory board supplier who answers “we are not a plastic supplier” when asked about USP <661> has missed the point. The paperboard is part of the packaging system that the chapter covers, and the procurement team needs the paperboard supplier to provide the biocompatibility test reports and the materials-of-construction statement that the system-level USP <661> review depends on.

USP <87> and USP <88>: the biocompatibility tests

Two USP chapters sit under the <661> framework and provide the actual test methods. USP General Chapter <87> is the Biological Reactivity Tests, In Vitro — a cytotoxicity test using cell culture that screens the finished board for leachates that would kill or stress mammalian cells. USP General Chapter <88> is the Biological Reactivity Tests, In Vivo — systemic and intracutaneous reactivity in live animals, run when the in vitro result warrants it.

For a pharmaceutical folding carton paperboard, USP <87> is the standard screening test the converter will run on the production batch. USP <88> is run if the <87> result is ambiguous or if the drug product manufacturer’s qualification program specifically calls for it. A Ningbo ivory board supplier that has USP <87> reports on file for the actual production board (not a generic pre-shipment sample) clears the typical pharmaceutical qualification gate.

What FDA 21 CFR 174–179 Covers for Paper and Paperboard

The US FDA regulations for indirect food additives in 21 CFR Parts 174 through 179 cover the components of paper and paperboard in contact with food, and by extension with drug products in most jurisdictions. The relevant sections include:

• 21 CFR 176.170 — components of paper and paperboard in contact with aqueous and fatty foods (the closest the FDA gets to a general paper-contact rule).
• 21 CFR 176.180 — components of paper and paperboard in contact with dry food.
• 21 CFR 176.170 listing — the specific substances permitted in paper and paperboard for food contact, including defoamers, slimicides, sizing agents, and coating additives.

The practical implication for a Ningbo ivory board supplier selling into the US pharmaceutical market is that every additive used in the manufacturing process — the defoamer in the wet end, the slimicide in the white water loop, the surface size, the coating binder — needs to be on the FDA’s list of permitted substances for the relevant contact condition. A paperboard mill that uses an additive not on the FDA list is not qualified for the US pharmaceutical market, regardless of how clean the fiber is.

The full regulations are accessible via the US Government’s electronic Code of Federal Regulations (eCFR), with 21 CFR Part 211 (GMP for Finished Pharmaceuticals) setting the broader packaging-component framework that the paperboard sits within.

What ICH Q3D Adds: Elemental Impurities

ICH Q3D is the International Council for Harmonisation guideline for Elemental Impurities in Drug Products. It sets permitted daily exposure (PDE) limits for trace elements that can leach from packaging components into the drug product over the shelf life. The relevant elements are lead, arsenic, cadmium, mercury, and a handful of others depending on the dosage form and route of administration.

For a paperboard folding carton, ICH Q3D applies to the inks, coatings, adhesives, and any metal-based additives used in the finishing. The bleached pulp fiber itself is not a meaningful source of elemental impurities; the risk is in the surface chemistry of the finished board. A Ningbo ivory board supplier selling into the pharmaceutical market needs to be able to document an elemental impurity risk assessment per ICH Q3D for the finished board, not for the fiber alone.

The ICH Q-series guidelines (Q3D for elemental impurities, Q3C for residual solvents, Q9 for quality risk management) are publicly available on the ICH Quality Guidelines page.

What the European Pharmacopoeia Adds

For drug products marketed in the EU, the European Pharmacopoeia (Ph. Eur.), published by the European Directorate for the Quality of Medicines and HealthCare (EDQM), sets the binding monographs. For paper and paperboard in pharmaceutical use, the Ph. Eur. references material expectations through the materials-of-construction framework rather than a dedicated paper chapter, which is why USP <661> and the corresponding ICH guidelines have become the de facto international standard.

For a Ningbo ivory board supplier selling into the EU pharmaceutical market, the practical expectation is a compliance dossier that addresses both the Ph. Eur. framework and the EU’s food-contact regulation (EC) No 1935/2004 where the paperboard is in contact with food or food-simulant conditions.

The Procurement Documentation Stack

A Ningbo ivory board supplier selling into the pharmaceutical folding carton market needs to have on file:

A Ningbo ivory board mill that already runs this documentation stack as standing capability is the one that wins the order. The mill that has to gather the documents after the converter asks typically loses 2–3 months on the qualification cycle.

Why This Matters for Ningbo Ivory Board Suppliers

The pharmaceutical market is small compared to cosmetics or food packaging, but it is a high-margin, low-volume-elasticity segment where compliance documentation is a barrier to entry. A Ningbo ivory board mill that qualifies into two or three pharmaceutical converter programs has built a stable revenue line that is largely insulated from the price pressure of the commodity industrial paper market.

The cost of qualifying is real — running USP <87> on a production board costs roughly the same as the board itself for a small batch, and the per-shipment compliance paperwork adds to administrative cost. But the margin on a qualified pharmaceutical-grade SBB C1S order is several times the margin on the same volume of commodity FBB. For a Ningbo mill that already has the test reports, the ISO 15378 audit, and the compliance letters on file, the marginal cost of taking a pharmaceutical order is low and the return is high.

How to Choose an SBB C1S Ivory Board for a Pharmaceutical Program

A practical checklist for a procurement team qualifying a Ningbo ivory board mill for a pharmaceutical folding carton program:

1. Confirm the grade is SBB C1S (not FBB GC1/GC2) and the specific GSM range matches the converter’s converting spec.
2. Verify the mill has USP <87> reports on file for the actual production board, run within the past 12 months.
3. Verify the mill’s 21 CFR 174–179 compliance letter covers all additives used in the manufacturing process, including defoamers, slimicides, sizing agents, and coating binders.
4. Verify the ICH Q3D elemental impurity risk assessment covers the inks, coatings, and adhesives used on the finished board.
5. Confirm the mill holds ISO 15378 certification (or is in active audit cycle for it).
6. Confirm per-shipment COA is the standard practice, not a special-order add-on.
7. Audit the converter’s sample-round blister lamination performance before committing to a production order.

A Ningbo mill that can show all seven items in a single email, with current test reports attached, is the mill that closes the pharmaceutical order. The seven-item checklist is the same checklist the drug product manufacturer’s qualification team runs. The mill that can satisfy the checklist is the mill that converts the audit into a production contract.

FAQ

← Ivory board range · Industrial paper → · Contact Us